{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.684","upperLimit":"0.885","value":"0.806"},{"groupId":"OG001","lowerLimit":"0.805","upperLimit":"0.963","value":"0.914"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"53"}],"units":"Participants"}],"description":"Kaplan-Meier estimate of probability of OS at the end of the month 6 from randomization.","dispersionType":"95% Confidence Interval","groups":[{"description":"Azacitidine 75 mg/m\\^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).","id":"OG000","title":"Azacitidine 75 mg/m^2"},{"description":"Azacitidine 75 mg/m\\^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 and pevonedistat 20 mg/m\\^2, infusion, intravenously, on Days 1, 3, and 5 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).","id":"OG001","title":"Azacitidine 75 mg/m^2 + Pevonedistat 20 mg/m^2"}],"paramType":"NUMBER","populationDescription":"ITT Population was defined as all participants who were randomized. Overall number analyzed are the number of participants with data available for analyses.","reportingStatus":"POSTED","timeFrame":"Month 6","title":"Six-month Survival Rate","type":"SECONDARY","unitOfMeasure":"survival probability"}